Luis Paz-Ares

Sep 10, 2023 | ascopubs.org | Helena A. Yu |James Yang |Martin Reck |Luis Paz-Ares

After tumor progression with EGFR TKI therapy and PBC in patients with EGFR -mutated NSCLC, HER3-DXd once every 3 weeks demonstrated clinically meaningful efficacy with durable responses, including in CNS metastases. A phase III trial in EGFR- mutated NSCLC after progression on an EGFR TKI is ongoing (HERTHENA-Lung02; ClinicalTrials.gov identifier: NCT05338970 ).

Sep 10, 2023 | brnw.ch | Helena A. Yu |James Yang |Martin Reck |Luis Paz-Ares

For patients with epidermal growth factor receptor (EGFR)–mutated advanced non–small-cell lung cancer (NSCLC), initial treatment typically includes one or two EGFR tyrosine kinase inhibitor (TKI) regimens comprising either a third-generation EGFR TKI or a first- or second-generation EGFR TKI followed by a third-generation EGFR TKI when the EGFR T790M mutation is detected.1 After disease progression on EGFR TKI therapy, patients are usually treated with platinum-based chemotherapy (PBC; with...

Jun 28, 2023 | onclive.com | Luis Paz-Ares

Luis Paz-Ares, MD, PhD, chairman, Medical Oncology Department, Hospital Doce de Octubre; head, Lung Cancer Unit, CNIO (National Oncology Research Center); associate professor, Universidad Complutense, discusses efficacy and safety findings from the phase 2 CARMEN-LC05 trial (NCT04524689) of tusamitamab ravtansine (SAR408701) in patients with nonsquamous non–small cell lung cancer (NSCLC) with CEACAM5 expression.

May 10, 2023 | onclive.com | Luis Paz-Ares

Luis G. Paz-Ares, MD, PhD, chair, the Medical Oncology Department, the Hospital Universitario 12 de Octubre, associate professor, the Universidad Complutense de Madrid, head, the Lung Cancer Unit, the National Oncology Research Center, discusses the importance of next-generation sequencing (NGS) and highlights current challenges with NGS for patients with non–small cell lung cancer (NSCLC).